The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said Sunday its revenue increased 1.7% year-on-year to 10.27 billion yuan ($1.4 billion) in the third quarter, as measured using Chinese GAAP. But its net profit fell 16.2% to 907 million yuan.

Looking up: Despite the profit decline, the company’s net cash flow from operating activities increased 3.4% year-over-year to 1.35 billion yuan in the latest quarter.

Take Note: The company’s revenue grew 26% in the first half of this year to 2.13 billion yuan, much higher than the 1.7% increase in the third quarter, meaning its business slowed significantly in the latest period.

Digging Deeper: Fosun Pharm is a diversified drug company whose portfolio includes pharmaceutical, medical equipment and healthcare services. Of its 21.3 billion yuan in first-half revenue, about 67% came from the pharmaceutical manufacturing business, while medical devices and medical diagnostic and healthcare services accounted for about 19% and 14%, respectively. The company said it is aiming to build a regional healthcare model and health services industry chain. As part of that, it spent nearly 1 billion yuan to acquire 60% of one of the largest private oncology specialty medical centers in Singapore in June.

Market Reaction: Fosun Pharmaceutical shares rose 8.1% on Monday morning, and were up 3.9% at HK$20.1 at the midday break. The stock currently trades near the lower end of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

So-Young dolls up with move to high-end cosmetic surgery

So-Young dolls up with pivot to high-end services

The cosmetic services social media platform is developing its own clinics as well as a premium platform for high-end users Key Takeaways: So-Young reported an annual profit last year, reversing…

NEWS WRAP: Nayuki pours up first annual profit

The premium tea chain aims to expand through franchising to boost its growth amid intense competition  By Teri Yu  Premium tea seller Nayuki Holdings Ltd. (2150.HK) on Wednesday reported its first annual profit since…
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…